目的 系統(tǒng)評(píng)價(jià)丹莪婦康煎膏治療子宮內(nèi)膜異位癥及其術(shù)后的有效性和安全性。方法 計(jì)算機(jī)檢索中國(guó)學(xué)術(shù)期刊全文數(shù)據(jù)庫(kù)（CNKI）、萬(wàn)方數(shù)據(jù)庫(kù)（Wanfang Data）、維普中文科技期刊數(shù)據(jù)庫(kù)（VIP）、中國(guó)生物醫(yī)學(xué)文獻(xiàn)服務(wù)系統(tǒng)（SinoMed）、PubMed、Cochrane Library和Web of Science數(shù)據(jù)庫(kù)中，關(guān)于丹莪婦康煎膏治療子宮內(nèi)膜異位癥的隨機(jī)對(duì)照試驗(yàn)（RCT），檢索時(shí)限為建庫(kù)起至2023年9月3日。通過(guò)Cochrane偏倚風(fēng)險(xiǎn)評(píng)估工具評(píng)估文獻(xiàn)質(zhì)量，采用RevMan 5.4.1軟件進(jìn)行Meta分析。結(jié)果 共納入21個(gè)RCTs，Meta分析結(jié)果顯示：?jiǎn)为?dú)使用丹莪婦康煎膏治療子宮內(nèi)膜異位癥的臨床總有效率［RR＝1.07，95% CI （1.01，1.13），P=0.01］、疼痛視覺(jué)模擬量表（VAS）評(píng)分［MD＝-1.59，95% CI （- 2.70，-0.47），P=0.005］、血清糖類抗原125（CA125）［MD＝-5.91，95% CI（-8.85，-2.97），P＜0.000 01］均優(yōu)于單獨(dú)使用孕三烯酮，差異均具有統(tǒng)計(jì)學(xué)意義；單獨(dú)使用丹莪婦康煎膏治療子宮內(nèi)膜異位癥的臨床總有效率［RR＝1.23，95% CI（0.91，1.65），P=0.18］優(yōu)于單獨(dú)使用米非司酮，差異無(wú)統(tǒng)計(jì)學(xué)意義。單獨(dú)使用丹莪婦康煎膏治療子宮內(nèi)膜異位癥的不良事件發(fā)生率［MD＝0.18，95% CI（0.10，0.32），P＜0.000 001］低于單獨(dú)使用孕三烯酮，差異具有統(tǒng)計(jì)學(xué)意義。結(jié)論 丹莪婦康煎膏治療子宮內(nèi)膜異位癥具有較好的有效性和安全性。

Objective To evaluate the efficacy and safety of Dan'e Fukang Decoction in the treatment of endometriosis (EMs). Methods Databases such as CNKI, Wangfang Data, VIP, SinoMed, PubMed, Cochrane Library and Web of Science were searched by computer for randomized controlled trials (RCT) of Dan'e Fukang Decoction in the treatment of EMs from database establishment to September 3, 2023. After literature screening, evaluate literature quality by Cochrane information extraction and deviation risk included in the evaluation study, Meta-analysis was performed using RevMan 5.4.1 software. Results A total of 21 RCTs were included. Meta-analysis showed that Dan'e Fukang Decoction was superior to gastronome in the clinical response rate of Ems [RR=1.07, 95%CI(1.01, 1.13), P=0.01], pain visual analogue scale (VAS) score [MD=-1.59, 95%CI (-2.70, -0.47), P=0.005], serum cancer antigen CA125 level [MD=-5.91, 95%CI (-8.85, -2.97), P＜0.000 01], and the differences were statistically significant; Dan'e Fukang Decoction was superior to mifepristone in the clinical response rate of Ems [RR=1.23, 95%CI (0.91, 1.65), P=0.18]. The incidence of adverse events in EMs treated with Dan'e Fukang Decoction alone [MD=0.18, 95%CI (0.10, 0.32), P＜0.000 001] was lower than that with gestrinone alone, and the difference was statistically significant. Conclusion Dan'e Fukang Decoction has good efficacy and safety in the treatment of EMs.

R285.5；R969.3

中央高?；究蒲袠I(yè)務(wù)專項(xiàng)資助項(xiàng)目（2020-JYB-ZDGG-072）